Dan Dunham has been named vice president of compliance at Astellas Pharma US, Inc. Mr. Dunham will be responsible for governance of the compliance program to ensure the company’s adherence to federal and state healthcare program requirements and regulations.

"We are very pleased to add Dan to our senior management team to provide strategic direction and leadership for the compliance department," said Seigo Kashii, president and chief executive officer of Astellas. "He brings with him 30 years of legal, compliance and extensive pharmaceutical experience, which will accelerate Astellas toward our company goals."

Prior to joining Astellas, Mr. Dunham held legal positions at Pfizer, Pharmacia and Warner-Lambert. He managed civil and criminal investigations into manufacturing, laboratory, marketing and promotion and pricing practices, and supervised a docket of domestic and international commercial and products liability lawsuits. While at Warner-Lambert, he created and implemented the company's worldwide corporate compliance program and office.

Sartorius Stedim Biotech (SSB) received several large orders for consumables used in biopharmaceutical production from leading global vaccine manufacturers. These items include specialty filters, aseptic single-use bags and other disposables for sterile filtration of pharmaceutical liquids and for storage and transport of intermediate serum products.

The orders are related to A(H1N1) flu vaccine testing and the expected startup of production operations. Governments from many countries have been requesting significant quantities of the vaccine from these producers in an effort to stockpile a sufficient supply. SSB supplies products both for classic, egg-based vaccine production and innovative cell culture-based processes using bioreactors.

"We are carefully tracking the situation and are in close contact with our global customers so we are well prepared," said Dr. Joachim Kreuzburg, chief executive officer of SSB. "Apart from the current situation we are facing with the outbreak of swine flu, we have long understood the growing importance of the vaccine market and have been developing appropriate products, especially for flexible single-use."

Sentry Logistic Solutions, Inc. has changed its name to Sentry BioPharma Services, Inc. The change is intended to represent the company’s enhanced service offerings and market focus.

“As our company has matured over the past four years, we decided this is an ideal time to improve our branding to better represent the organization” said Jennifer Marcum, chief executive officer of Sentry BioPharma Services. “We believe our new name better reflects our evolution into a contract biopharmaceutical service provider addressing labeling and packaging, supply chain management, coordinated global distribution and fulfillment services supporting high value and stringently regulated legend drug products and materials.”

News from our sister sites